Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Fox Chase Cancer Center, Philadelphia
Low-dose estrogen and fulvestrant are proposed to maintain tumor control
February 5th, 2006
Low-dose estrogen and fulvestrant is proposed as a debulking strategy to maintain tumor control in breast cancer patients. "Long-term antihormonal therapy is effective at controlling the recurrence of estrogen receptor (ER)-positive breast cancer, but there may be unanticipated consequences for the development of new forms of drug resistance. Laboratory studies of exhaustive antihormonal therapy demonstrate there are at least two phases of resistance to selective ER modulators (SERMs; tamoxifen and raloxifene) and to estrogen withdrawal (aromatase inhibitors)," stated scientists in the United States. "In Phase I drug resistance, estrogen or a SERM...
Source: Women's Health Law Weekly (2006-02-05)
|
